Press release from Companies

Publicerat: 2022-07-18 07:58:11

Inhalation Sciences Sweden AB: Inhalation Research Services chosen for new research project worth 1.45 million SEK by US pharma company

(Stockholm 18 July 2022) A US company with an extensive pipeline in medical dermatology has chosen Inhalation Research Services (IRS), ISAB’s contract research organization, for a research project worth 1.45 million SEK (1.36 K Euro) into a new repurposed drug that is being reformulated for administration via the lungs. ISAB’s world-class expertise in inhalation, and its high-precision IPL (Isolated Perfused Lung) solution, were decisive in the client’s choice.

The new US client has chosen ISAB’s ex vivo IPL (Isolated Perfused Lung) solution to test its new repurposed drug that is being reformulated for administration via the lungs. ISAB’s version of IPL is a highly lung-specific methodology that is specially tailored for aerosols generated by its PreciseInhale® system. It bypasses any potential delivery issues with in vivo exposures and will deliver high-precision (Standard Derivation is typically below 10%) and high-resolution PK data.

Both dermatology and the repurposing of drugs are high-growth areas within the pharmaceutical industry. The reduced development time and costs of repurposing drugs to treat new indications has led to significant market growth and an increase in the number of research projects.

ISAB CEO Manoush Masarrat: "as we stated earlier this year, we have intensified our efforts within Inhalation Research Services. We are pleased to start this fascinating project with a new customer from the US, one of our key markets. We look forward to delivering them high-value knowledge and data that will help reduce risk and accelerate development right from the very start of their project."

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on July 18, 2022.

Läs mer hos Cision
Läs mer om Inhalation Sciences Sweden AB